Sugentech Inc. (KOSDAQ:253840)

Market Cap	93.57B -20.7%
Revenue (ttm)	9.01B -7.2%
Net Income	-20.81B
EPS	-1,363.97
Shares Out	15.29M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	404,205
Average Volume	447,451
Open	6,070.00
Previous Close	6,120.00
Day's Range	5,800.00 - 6,150.00
52-Week Range	4,910.00 - 9,390.00
Beta	0.54
RSI	46.33
Earnings Date	Feb 27, 2026

About Sugentech

Sugentech Inc. develops and sells in-vitro diagnostic systems and products based on biotechnology, information technology, and nanotechnology in South Korea and internationally. The company offers lab tests, including systems and test items; and COVID-19 tests. It also provides point of care testing analyzers and test items for testing of influenza A/B, antibody test, COVID-19 and flu, SARS-CoV-2, HbA1c, beta-hcg, YSH, T3/T4, and CRP; and digital health and home tests, including mobile health, ovulation, and pregnancy products. The company was ...

• Industry: Medical - Specialties
• Sector: Healthcare
• Founded: 2011
• Employees: 144
• Stock Exchange: KOSDAQ
• Ticker Symbol: 253840

Financial Performance

In 2024, Sugentech's revenue was 10.10 billion, an increase of 41.57% compared to the previous year's 7.13 billion. Losses were -15.19 billion, -11.87% less than in 2023.